Pegvisomant in acromegaly: an update

BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety. AIM: We here reviewed the emerging aspects of the us...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Endocrinol Invest
Main Authors: Giustina, A., Arnaldi, G., Bogazzi, F., Cannavò, S., Colao, A., De Marinis, L., De Menis, E., Degli Uberti, E., Giorgino, F., Grottoli, S., Lania, A. G., Maffei, P., Pivonello, R., Ghigo, E.
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2017
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5443862/
https://ncbi.nlm.nih.gov/pubmed/28176221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40618-017-0614-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki